Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication (Completed)
The Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) study is a large-scale, international, multi-centre, randomised, double-blind, controlled, 2x2 factorial design trial which aims to determine if treatment with an ACE inhibitor (ramipril) and/or a thiazolidinedione (rosiglitazone) can delay or prevent the development of type 2 diabetes (T2DM) in people with impaired glucose tolerance (IGT) or impaired fasting glucose (IFG). Recruitment commenced in July 2001 and ended in August 2003. A total of 5269 patients (4531 IGT and 738 IFG) have been recruited and will be followed for a minimum of three years with regular assessment to ascertain the occurrence of the primary outcome (new onset T2DM or all cause mortality) as well as predefined secondary outcomes. The study is co-ordinated by the Canadian Cardiovascular Collaboration (CCC) at McMaster University, Hamilton, Canada. European sites are managed by the EuroDREAM project office (see contact details below) at the Diabetes Trials Unit, Oxford Centre for Diabetes, Endocrinology and Metabolism, Oxford, UK.